STANDARD BIOTOOLS INC. (LAB) Form 10-Q — Nov 3, 2026
Standard BioTools reported Q3 2026 revenue of $19.4 million, down about 1% year over year, with a net loss from continuing operations of $15.0 million, though net income was positive $13.5 million thanks to a $30.0 million gain from terminating its Illumina earnout and royalty agreements. The company recognized a $202.3 million total pre-tax gain on the sale of its SomaScan Business to Illumina, which closed January 30, 2026 and generated $410.7 million in net cash proceeds, lifting cash to $267.5 million.
Key figures
- Eps
- 0.03
- Revenue
- 19385000
- Net Income
- 13483000
- Revenue Yoy
- -0.9% (Q3 2026 total revenue $19.385M vs $19.552M Q3 2025)
- Total Assets
- 635332000
- Cash Position
- 267487000
- Shares Outstanding
- 394790441
- Cvr max shares
- 76000000
- Gross margin q3
- 56% vs 49% year-ago
- Nine month net income
- 113793000
- Treeline equity value
- $2.5B (vs LAB $460M)
- Microfluidics sale price
- 5000000
- Nine month total revenue
- 60635000
- Termination fee treeline
- 16100000
- Mass cytometry sale price
- 5500000
- Pretax gain somascan sale
- 202300000
- Somascan net cash proceeds
- 410700000
AI analysis
Red flags6 · Pro
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.